Posts by: Inês Martins PhD

Inês Martins PhD

Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.

May 11, 2020May 11, 2020

Hydralazine Causes Rare Case of AAV with Severe Respiratory, Kidney Failure, Study Reports

News

A common blood pressure medication called hydralazine may cause ANCA-associated vasculitis (AAV), with a severe impact on both lungs and kidneys in rare instances, a case report shows. The medication ... Read more

May 4, 2020May 4, 2020

AAV Linked to Inflammation, Thickening of Brain Membranes in Case Study

News

A rare case of ANCA-associated vasculitis (AAV) causing thickening of the dura mater — a protective membrane of the central nervous system (CNS) — was found in a person previously ... Read more

April 27, 2020April 27, 2020

Autoimmune COVID-19 Project Seeks Patient Input About Pandemic

News

To better understand the concerns and behaviors of people with autoimmune conditions during the COVID-19 pandemic, the Global Healthy Living Foundation (GHLF) and its digital patient community, CreakyJoints, have launched a ... Read more

April 20, 2020April 20, 2020

MS Medication Lemtrada May Cause Life-threatening ANCA Vasculitis, Case Report Shows

News

The multiple sclerosis treatment Lemtrada (alemtuzumab) can cause severe ANCA-associated vasculitis in rare cases, adding to the growing number of autoimmune complications caused by this therapy, a case report shows. ... Read more

April 13, 2020April 13, 2020

High Steroid Dose, Kidney Problems Tied to Severe Infections in Elderly with AAV

News

High doses of corticosteroids as initial treatment and kidney problems evident at diagnosis significantly increase the likelihood of early and severe infections in elderly people with ANCA-associated vasculitis (AAV), research ... Read more

March 11, 2019

Rise in MPO-ANCA Antibodies After Remission May Predict Relapse

News

Among ANCA-associated vasculitis patients in remission — particularly those with manifestations in their kidneys — the reappearance of MPO-ANCA antibodies may be a sign of disease relapse, a study suggests. ... Read more

February 4, 2019

Belimumab Maintenance Fails to Delay Relapse in AAV Patients, Phase 3 Trial Suggests

News

A combination of belimumab plus standard maintenance treatment is no better than standard of care alone at delaying relapse in ANCA-associated vasculitis (AAV) patients in remission, a Phase 3 clinical trial shows. However, ... Read more

January 22, 2019

Mycophenolate Mofetil Can Replace Cyclophosphamide at Inducing Remission in Some AAV Patients, Clinical Trial Suggests

News

The immunosuppressant agent mycophenolate mofetil (MMF) is similar to standard cyclophosphamide at inducing remission in ANCA-associated vasculitis (AAV) patients, but it seems to be associated with a higher relapse rate, ... Read more

November 29, 2018

Early Disease Status Predicts Long-term Outcomes in AAV Patients, Study Suggests

News

Disease status at three and six months seems to predict long-term survival and kidney failure in patients with ANCA-associated vasculitis (AAV), a study shows. These findings suggest that early disease control ... Read more

October 23, 2018

FDA Expands Approval of Rituxan as Remission Maintenance Treatment for GPA and MPA Patients

News

The U.S. Food and Drug Administration has approved a label update for Rituxan (rituximab) to include information for patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) who have ... Read more